SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Community expansion. Collaboration, of new members. Cooperate on project development. Find like-minded people, join the team. Spread influence and power.
Mergers & acquisitions
Alcon Secures Majority Stake in Aurion, Deposes CEO
Last month, Deerfield Management accused Alcon of obstructing Aurion’s IPO plans so it could acquire the startup “at a discount.”
March 27, 2025
 · 
1 min read
 · 
Tristan Manalac
Regulatory and safety control measures in pharmaceutical industry banner. Drug regulations, safety controls FDA ensuring the quality of pharmaceutical products, vector illustration isolated on white.
Approvals
Soleno Wins First FDA Approval for Hyperphagia in Prader-Willi Syndrome
Soleno’s Vykat XR is the first drug approved for the rare disease that directly targets its hallmark symptom.
March 27, 2025
 · 
2 min read
 · 
Tristan Manalac
Pictured: J&J's office in Madrid, Spain
Lung cancer
J&J’s Lung Cancer Combo Bests AstraZeneca’s Tagrisso, Reducing Risk of Death 25%
The latest data from Johnson and Johnson’s Rybrevant and Lazcluze lung cancer combo was better than standard of care Tagrisso on overall survival. But analysts say the next step is getting a subcutaneous formula approved.
March 27, 2025
 · 
2 min read
 · 
Tristan Manalac
Histology microscope image of motor unit synapse of muscle fibers (100x)
Duchenne muscular dystrophy
Safety Questions Loom in Duchenne as Dyne, Wave and Others Plan FDA Filings
Several companies will head to the FDA seeking approval of new Duchenne muscular dystrophy treatments next year but the death of a patient taking Sarepta’s Elevidys raises important safety questions.
March 27, 2025
 · 
8 min read
 · 
Heather McKenzie
caute cartoon businesspeople stand on hands with blue backgroound
China
Bayer Jumps on Chinese Partnership Train with Oncology Deal
The German conglomerate announced a licensing agreement with Puhe BioPharma for a PRMT5 inhibitor used in a variety of cancers. Financial details of the deal were not disclosed.
March 26, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Abstract oriental Japanese art vector background in red color, traditional style design, wavy shapes and mountains terrain landscape, runny like sea lines.
Duchenne muscular dystrophy
Wave’s Duchenne Exon-Skipper Reverses Muscle Damage in Mid-Stage Trial
WVE-N531, an oligonucleotide, elicited significant functional benefit and reversal of muscle damage in the Phase II FORWARD-53 trial. Wave plans to file for accelerated approval of the candidate in 2026.
March 26, 2025
 · 
3 min read
 · 
Heather McKenzie
Interest rate and tax concept. A percentage symbol and arrow symbol on wooden cube. Interest rates continue to increase, return on stocks and mutual. funds, finance, growth, increase, profit. FED.
Government
Tariffs Would Impede Access to Affordable Drugs, Industry Warns
Donald Trump’s proposed tariffs on the EU would increase manufacturing costs for pharma companies and would stall medical innovation, according to the results of a recent survey by the Biotechnology Innovation Organization.
March 26, 2025
 · 
2 min read
 · 
Tristan Manalac
Paper human heads with colorful puzzle pieces on a light background. World autism day concept
Alzheimer’s disease
Eisai Lowers Sales Expectations for Leqembi Again, Citing Slow US Uptake
Eisai’s new fiscal 2027 forecast for Leqembi is roughly 50% lower than its projections a year ago.
March 26, 2025
 · 
2 min read
 · 
Tristan Manalac
A doctor's hand in a blue medical glove holding a jar of medicine or vitamins on a blue background with copy space. Vector illustration in flat style
FDA
GSK Wins FDA Nod for First Oral UTI Antibiotic in Almost 30 Years
Blujepa, which treats UTIs in female patients aged 12 and up with common and uncomplicated infections, will hit the market in the second half of this year.
March 26, 2025
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS